Premature Trial Suspension Will Inevitably Alter Equipoise To the Editor: The research report by the EVA-3S Investigators1 has implications which could far exceed their understandable desire to optimize safety within the trial. Following an early interim analysis, the investigators observed that the death/stroke rate after unprotected carotid angioplasty was 10.3% (6/58), as compared with 26.7%...